Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause

@article{Unkila2013VaginalEO,
  title={Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause},
  author={Mikko Unkila and Seppo Juhani Kari and Emrah Yatkin and Risto A. S. Lammintausta},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={2013},
  volume={138},
  pages={107-115}
}

Figures and Tables from this paper

Tissue selectivity of ospemifene: Pharmacologic profile and clinical implications
Effects of ospemifene on vaginal epithelium of post-menopausal women
TLDR
In postmenopausal women affected by VVA, 1 month intake of ospemifene is associated with an increased maturation, and ERα expression of the vaginal mucosa, which may partially explain the improvement of symptoms of vaginal atrophy reported with this drug.
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
TLDR
Available evidence indicates that ospemifene has unique effects on tissue, leading to a favorable long-term profile for the relief of vulvar and vaginal atrophy compared with other estrogen receptor agonists/antagonists with no short-term concerns about endometrial safety.
Effects of vaginal conjugated equine estrogens and ospemifene on the rat vaginal wall and lower urinary tract
TLDR
Unless contraindicated, the beneficial effects of vaginal CEE on the vaginal wall outweigh those of OS, and ospemifene alters vaginal epithelium in a unique way that is additive with local estrogen.
Eto , C Ospemifene versus Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
TLDR
This study hopes to determine if ospemifene is superior to conjugated estrogens in improving sexual function and vaginal atrophy symptoms and may provide an attractive alternative to the many women who continue to suffer from sexual dysfunction and VVA because of concerns surrounding the use of exogenous hormones.
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
TLDR
Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index, decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo.
Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use
TLDR
Ospemifene is an approved oral option for postmenopausal women seeking treatment for VVA with bothersome dyspareunia, particularly for those who have tried and failed over-the-counter options or do not want vaginal therapies.
Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause
TLDR
Preclinical and clinical data describing the safety and efficacy of ospemifene for vaginal dryness and dyspareunia due to VVA and its effects on sexual function were reviewed.
Ospemifene: a safe treatment of vaginal atrophy
TLDR
Ospemifene relieves moderate to severe symptoms of vulvovaginal atrophy, like dryness, irritation and soreness around the genital area, and painful sexual intercourse, in menopausal women, and it has neutral effects on endometrium and coagulation.
...
1
2
3
...

References

SHOWING 1-10 OF 41 REFERENCES
Ospemifene use in postmenopausal women
TLDR
The recently released results from a pivotal Phase III study in postmenopausal women demonstrated statistically significant improvements of ospemifene 60 mg/day in symptoms of vulvar and vaginal atrophy over the use of non-hormonal vaginal lubricant.
Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women
TLDR
Ospemifene, at the dose of 90 mg/day, was more estrogenic than raloxifenes, as shown by changes in serum follicle-stimulating hormone and sex hormone-binding globulin levels.
Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice
Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy
TLDR
In this study, once-daily oral ospemifene 60 mg was effective for the treatment of vulvar and vaginal atrophy in postmenopausal women with dyspareunia.
Molecular analysis of the vaginal response to estrogens in the ovariectomized rat and postmenopausal woman
TLDR
At the transcriptional level, there is evidence of significant overlap of the effects of estrogen treatment between the OVX rat and human VA samples.
Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor &bgr; and androgen receptor in rats
TLDR
Lasofoxifene stimulated vaginal mucus formation without causing cell proliferation in the rat reproductive tract, and may be due to the increased vaginal estrogen receptor and androgen receptor levels.
Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats1.
TLDR
The bone-sparing, antitumor, and cholesterol-lowering effects of FC1271a combined with a low uterotropic activity and lack of liver toxicity indicate that FC 1271a could be an important alternative in planning antiosteoporosis therapy for estrogen deficiency.
Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.
TLDR
Bazedoxifene acetate represents a promising new treatment for osteoporosis, with a potential for less uterine and vasomotor effects than selective estrogen receptor modulators currently used in clinical practice.
Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study
TLDR
Ospemifene was shown to be effective and well tolerated for the treatment of the symptoms of vaginal dryness and dyspareunia associated with vulvovaginal atrophy over and above the use of provided lubricants.
...
1
2
3
4
5
...